

Draft agenda
50th meeting of the Biocidal Products Committee (BPC)
26-27 & 29 February 2024
Meeting is held virtually in Webex

**Starts on 26 February at 10:30,
ends on 29 February at 17:00**
The time is indicated in Helsinki time.

1. – Welcome and apologies

2. – Agreement of the agenda

BPC-A-50-2024
For agreement

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-49

BPC-M-49-2023
For agreement

5. – Administrative issues

5.1. Administrative issues

For information

6. – Work programme for BPC

**6.1. BPC Work Programmes for active substance approval, Union
authorisation, ED assessment and outlook for BPC**

BPC-50-2024-6.1 A, B, C, D
For information

6.2. Update on active substance approval

For information

6.3. Update on Union Authorisation processes

For information

6.4. Update on article 75(1)(g) mandates

For information

7. – Applications for approval of active substances*

7.1. Draft BPC opinion on the approval of 2-methyl-4-oxo-3-(prop-2-ynyl)cyclopent-2-en-1-yl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate (Prallethrin) for PT 18

Previous discussion: WG-IV-2023

BPC-50-2024-7.1 A, B, C

For adoption

7.2. Draft BPC opinion on the approval of Silver zinc zeolite for PT 2, 7, 9

Previous discussions: TM-II-2013, TM-IV-2013, WG-III-2015, WG-III-2016, WG-V-2016, WG-V-2017, BPC-27, BPC 28, WG-IV-2023

BPC-50-2024-7.2 A, B, C

For adoption

7.3. Draft BPC opinion on the renewal of Cholecalciferol for PT14

BPC-50-2024-7.3 A, B, C

For adoption

7.4. Evaluation of post-approval data submitted for cypermethrin for PT 18

Previous discussion: WG-III-2023

BPC-49-2023-7.4 A, B, C

For adoption

8. – Union authorisation**

8.1. Member state experience in rejecting Union Authorisation

BPC-50-2024-8.1 A

For information

8.2. Draft BPC opinion on the Union Authorisation of a biocidal product family containing L-(+)-lactic acid for PT 3

Previous discussion: WG-IV-2023

BPC-50-2024-8.2 A, B, C, D, E

For adoption

* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

** For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product family (denoted by E).

8.3. Draft BPC opinion on the Union Authorisation of a biocidal product family containing Hydrogen peroxide for PT 2, 4

Previous discussion: WG-IV-2023

BPC-50-2024-8.3 A, B, C, D, E

For adoption

8.4. Draft BPC opinion on the Union Authorisation of a biocidal product containing N-cyclopropyl-1,3,5-triazine-2,4,6-triamine (Cyromazine) for PT 18

Previous discussion: WG-IV-2023

BPC-50-2024-8.4 A, B, C, D, E

For adoption

8.5. Minor updates to the procedures for minor change applications of Union authorisation and revision of the linguistic check of SPC translations of Union authorisation of same biocidal products

BPC-50-2024-8.5 A, B

For information

8.6. e-Consultation: PT designation of surface disinfectant in healthcare areas

BPC-50-2024-8.6 A

For information & for agreement

9. - Article 75(1)(g) opinion requests

9.1 Impact of the use of azole fungicides, other than as human medicines, on the development of azole-resistant *Aspergillus* spp.

Previous discussion: BPC-46

BPC-50-2024-9.1 A

For information

10. - Any other business

11. - Action points and conclusions

**Provisional time schedule for the
50th meeting of the Biocidal Products Committee (BPC)
Virtual meeting in WebEx**

Please note that the time schedule indicated below is provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following day for BPC opinions.

Monday 26 February: (starts at 10:30 EET/09:30 CET, ends at 17:00 EET/16:00 CET)

Items 1-5	Opening items and administrative issues
Item 6.1	BPC Work Programmes for active substance approval, Union authorisation, ED assessment and outlook for BPC
Item 6.2	Update on active substance approval
Item 6.3	Update on Union Authorisation processes
Item 6.4	Update on article 75(1)(g) mandates
Item 7.1	Draft BPC opinion on the approval of 2-methyl-4-oxo-3-(prop-2-ynyl)cyclopent-2-en-1-yl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate (Prallethrin) for PT 18
Item 7.2	Draft BPC opinion on the approval of Silver zinc zeolite for PT 2, 7, 9

Tuesday 27 February: (starts at 10:30 EET/09:30 CET, ends at 17:00 EET/16:00 CET)

Item 7.3	Draft BPC opinion on the renewal of Cholecalciferol for PT 14
Item 7.4	Evaluation of post-approval data submitted for cypermethrin for PT 18
Item 8.1	Member state experience in rejecting Union Authorisation
Item 8.2	Draft BPC opinion on the Union Authorisation of a biocidal product family containing L-(+)-lactic acid for PT 3

Thursday 29 February: (starts at 10:30 EET/09:30 CET, ends at 17:00 EET/16:00 CET)

Item 8.3	Draft BPC opinion on the Union Authorisation of a biocidal product family containing Hydrogen peroxide for PT 2, 4
Item 8.4	Draft BPC opinion on the Union Authorisation of a biocidal product containing N-cyclopropyl-1,3,5-triazine-2,4,6-triamine (Cyromazine) for PT 18
Item 8.5	Minor updates to the procedures for minor change applications of Union authorisation and revision of the linguistic check of SPC translations of Union authorisation of same biocidal products
Item 8.6	e-Consultation: PT designation of surface disinfectant in healthcare areas
Item 9.1	Impact of the use of azole fungicides, other than as human medicines, on the development of azole-resistant <i>Aspergillus</i> spp.
Item 10	Any other business
Item 11	Action points and conclusions

End of meeting

oOo